Top

Journal of Neuro-Oncology

Published in:

01-06-2014 | Letter to the Editor

ROS1 translocations and amplifications in lung cancer brain metastases

Authors: Matthias Preusser, Berthold Streubel, Peter Birner

Published in: Journal of Neuro-Oncology | Issue 2/2014

Excerpt

To the Editor, …

Davies KD, Doebele RC (2013) Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res 19:4040–4045PubMedCrossRef

Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-Kenudson M, Pao W, Iafrate AJ (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30:863–870PubMedCentralPubMedCrossRef

Preusser M, Berghoff AS, Ilhan-Mutlu A, Magerle M, Dinhof C, Widhalm G, Dieckmann K, Marosi C, Wohrer A, Hackl M, Zochbauer-Muller S, von Deimling A, Schoppmann SF, Zielinski CC, Streubel B, Birner P (2013) ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. Lung Cancer 80:278–283PubMedCrossRef

Title: ROS1 translocations and amplifications in lung cancer brain metastases
Authors: Matthias Preusser
Berthold Streubel
Peter Birner
Publication date: 01-06-2014
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2014
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-014-1446-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

ROS1 translocations and amplifications in lung cancer brain metastases

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2014

Pediatric posterior fossa ganglioglioma: unique MRI features and correlation with BRAF V600E mutation status

Yield and utility of routine postoperative imaging after resection of brain metastases

Karyopherin a2 and chromosome region maintenance protein 1 expression in meningiomas: novel biomarkers for recurrence and malignant progression

A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the brain tumor investigational consortium (BTIC)

Clinical management and outcome of histologically verified adult brainstem gliomas in Switzerland: a retrospective analysis of 21 patients

Decreased expression of LASS2 is associated with worse prognosis in meningiomas